Repros Seeks To Develop Low-Dose Proellex To Avoid Liver Toxicity
This article was originally published in The Pink Sheet Daily
Executive Summary
In a precarious financial situation, the company requests that FDA lift a clinical hold on the drug it is developing for uterine fibroids and endometriosis.
You may also be interested in...
Repros Low-Testosterone Therapy NDA May Be Delayed Until Q4 2014
The company is preparing two head-to-head studies against approved testosterone replacement therapies to try to demonstrate Androxal’s superiority, even as apparent data fraud at a study site may alter the final analysis of a pivotal Phase III study.
Repros Low-Testosterone Therapy NDA May Be Delayed Until 4Q 2014
The company is preparing two head-to-head studies against approved testosterone replacement therapies to try to demonstrate Androxal’s superiority, even as apparent data fraud at a study site may alter the final analysis of a pivotal Phase III study.
For Sale: Repros Suffers An FDA Clinical Hold And Potential NASDAQ Delisting
FDA asks Repros to determine whether a lower dose of Proellex will lessen liver toxicity risks, but the company is strapped for cash.